European Commission grants conditional approval for Nexpovio to treat multiple myeloma – Karyopharm Therapeutics
Karyopharm Therapeutics Inc. announced that the European Commission (EC) has granted conditional marketing authorization for Nexpovio (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine,… read more.
